Abolishing this gap filling role with an inhibitor that disrupts the interaction between REV1 and MAD2L2/REV3L is toxic to these HR-deficient cancer cells, including to PARP inhibitor-resistant BRCA1 mutant cells. This evidence concerns the gene MAD2L2 and cancer.